In addition to the six-min walk distance (6 MWD), other six-min walk test (6 MWT) derived variables, such as mean walk-speed (6MWSpeed), 6-min walk-work (6 MWW), distance-saturation product (DSP), exercise-induced oxygen desaturation (EID), and unintended stops may be useful for the prediction of mortality and hospitalization in patients with chronic obstructive pulmonary disease (COPD). We studied the association between 6 MWT-derived variables and mortality as well as hospitalization in COPD patients and compared it with the BODE index.
Introduction
The six-minute walk test (6 MWT) is a reliable, widely-used test to assess functional exercise performance in patients with chronic obstructive pulmonary disease (COPD) [1e3] . Its primary readout is the distance (meters) walked in six minutes (6 MWD) . A 6 MWD <350 m predicts an increased risk of hospitalization and mortality rates in COPD [4, 5] .
The 6 MWT is generally well tolerated, but some patients with COPD are unable to walk at a continuous pace for six minutes and need to stop to rest. Those unintended stops due to exerciseinduced symptoms such as dyspnea and leg discomfort may even lead to test discontinuation [6, 7] . Obviously, unintended stops significantly affect 6 MWD, and, in turn, may be the underlying reason that a poor 6 MWD is associated with mortality in patients with COPD. Indeed, unintended stops during corridor walking are associated with higher rates of mortality in older adults and should be evaluated [8e11] . Therefore, we hypothesized that unintended stop(s) during the 6 MWT may provide an additional prognostic information besides the 6 MWD of patients with COPD. In addition, other 6 MWT-derived outcomes, such as the average walking speed (6MWSpeed, m/sec of actual walking) [5, 9, 10] , the 6-min walk work (6 MWW, m kg; defined as the product of 6 MWD in meters and body weight in kilograms) [12, 13] , the distance-saturation product (DSP, in meters% defined as the product of the 6 MWD in meters and the lowest SpO 2 %) [14] , and the exercise-induced oxygen desaturation (EID; defined as a nadir SpO 2 88% in the 6 MWT) [15] might also possess significant prognostic value in identifying patients at high risk for mortality and hospitalization in COPD.
To date, little is known about the prognostic value of the above mentioned 6 MWT-derived variables in patients with COPD. Therefore, we sought to determine the prognostic value of the 6 MWT-derived variables exploring further data from the ECLIPSE study [16] .
We used the well validated BODE index [17, 18] , calculated from body mass index (B), degree of airflow obstruction as expressed by FEV 1 (O), dyspnea with the modified medical research council (D) and exercise (E) measured with the 6 MWD, as a comparator.
Material and methods

Design and participants
The ECLIPSE study (ClinicalTrials.gov identifier: NCT00292552; GSK study code SCO104960) was a 3-year non-interventional longitudinal prospective study. The inclusion and exclusion criteria of the ECLIPSE study have been described elsewhere [16] . In brief, individuals (age: 40e75 years) were recruited to the ECLIPSE if they had a smoking history of !10 pack-years and a diagnosis of COPD [19] . The ECLIPSE study was carried out in accordance with the Declaration of Helsinki and good clinical practice guidelines, and approved by the ethics committees of participating centers. The Institutional Review Boards of all participating institutions approved the study and all participants signed their informed consent.
Subject characterization
Demographic and physiological characteristics, level of dyspnea (using the modified Medical Research Council (mMRC) dyspnea scale) and measurements of lung function (post-bronchodilator spirometry and lung volumes), amount of emphysema (low-dose volumetric computed tomography [CT scan] 120 kV peak, 40 mA and 1.00 or 1.25-mm slice thickness), and exercise data (6 MWT; see below) were used for analyses. Fat mass and fat free mass were determined using bioelectrical impedance (Bodystat 1500). Fat free mass index (FFMI, kg/m 2 [2] ) was calculated as the mass (kg) divided by the squared height (m 2 ) and the body mass index (BMI, kg/m 2 ) was calculated as weight (kg) divided by squared height (m 2 ).
Six-minute walk test
The 6-min walk test was performed according to the 2002 ATS guidelines [20] . Briefly, participants were asked to walk indoors in a flat, straight, 30 m walking course supervised by a well-trained researcher. A practice 6MWT was not undertaken. Subjects were encouraged using standard methodology every minute of the 6 MWT [21] . They were allowed to stop and rest during the test, but were instructed to resume walking as soon as possible. Rest and post-exercise SpO 2 were measured using a pulse oximeter with a finger probe. A modified Borg scale was used to quantify the levels of dyspnea and fatigue perceived by subjects at the beginning and end of the test. The BODE index was calculated using the algorithm developed by Celli and colleagues [17] . We report that 6 MWT-data from the ECLIPSE study have been published before. Specifically, the association between baseline 6 MWD and outcomes; and between changes in 6 MWD and outcomes have been published [2, 22, 23] . The current study is complementary, as the 6 MWTderived variables and their associations with survival and hospitalization are novel. Several 6 MWT derived variables were used for analyses. The 6 MWD was recorded by measuring the actual walking distance in meters during the 6 MWT; 6MWSpeed was calculated by dividing the 6 MWD by the total walking time (6MWSpeed, m/ sec ¼ 6 MWD, m/walking time, sec) [5, 9] . For example, in a 6 MWD of 400 m during which patient have unintended stop(s) of a total duration of 30 s, the 6MWSpeed would be 1.2 m/sec (e.g. 400 m/ 330sec). 6 MWW was estimated by the product of body weight and walking distance (6 MWW,m kg ¼ 6 MWD, m Â body weight, kg) [12, 13] ; DSP was calculated as the product of the final distance walked in meters and the post-exercise SpO 2 % (DSP,m % ¼ 6 MWD,m Â SpO 2 %post/100) [14] ; EID was defined as the postexercise SpO 2 88% [15] . Unintended stops were defined as a (temporary) discontinuation of the 6 MWT. 
Statistical analyses
Subjects were classified as: (1) "Completers" or "Stoppers" according to their ability to complete without stop(s) the 6 MWT; (2) "Hospitalized" or "Non-hospitalized" according to !1 exacerbations requiring hospitalization during follow up (exacerbation-related hospitalization); and (3) "Survivors" or "Non-survivors" according to their vital status at the end of 3-year follow-up.
Results are shown as mean (±standard deviation) or proportion (%). The statistical significance of between-group differences was assessed using analysis of variance, paired T-tests and Chi-square test, as appropriate. Multiple comparisons were testing with one- Table 1 Demographics and baseline characteristics of patients categorized according to mortality and hospitalization.
Characteristics
All subjects (n ¼ 2010) 
Results
Study characteristics
A total of 2010 COPD patients with complete data was included in the study. As shown in Table 1 , subjects had normal BMI, moderate to severe airflow limitation (56% GOLD grade III or IV) and mild to severe emphysema on CT (34% had severe to very severe emphysema). The 53% of subjects had dyspnea (mMRC scale !2), 48% severely impaired health status (SGRQ Total Score !50 points), and 27% symptoms of depression (CES-D scale !16 points; Table 1 ). On average, subjects walked 372 (122) m; 6MWSpeed was 1.0 (0.3) m/s; 6 MWW was 28271 (11232) m kg; and DSP was 341 (117) m%. The 6 MWD was <350 m in 41% of the cohort, 23% exhibited EID, and 4% had unintended stops during the 6 MWT. The BODE index in the entire cohort was 3.1 (2.1) points (Table 1) .
Events during follow-up
A total of 193 subjects (10%) died during the 3-year follow-up. Non-survivors were older, had more severe airflow limitation, a higher degree of emphysema, higher dyspnea grades, and more impaired health status than survivors (Table 1 ). In addition, nonsurvivors had a lower baseline 6 MWD, 6MWSpeed, 6 MWW, DSP, a higher proportion of "stoppers", a higher proportion of patients with EID, and a higher BODE index ( Table 2 ). Similar differences were found between subjects with and without exacerbation-related hospitalization ( Tables 1 and 2) . Moreover, significant correlations were found amongst survival days, time to hospitalization and the several 6 MWT-derived variables (Online Table 1 ). The best detected cut-off points and the ROC parameters for the prediction of 3-year survival in the studied COPD population. The area under the curve (AUC) represents the expected performance of the best cut-off points for the predictive indexes. The best detected cut-off points and the ROC parameters for the prediction of 3-year hospitalization in the studied COPD population. The area under the curve (AUC) represents the expected performance of the best cut-off points for the predictive indexes.
Predictive value of 6 MWT-derived variables for mortality and hospitalization
Tables 3 and 4 present the threshold values with the best specificity and sensitivity to predict mortality and hospitalization during follow-up for the 6 MWD, 6MWSpeed, 6 MWW, DSP, and the BODE index (as a validated reference). The prognostic accuracy of these cut-off points did not vary significantly within different age groups, sex, GOLD stages and the degree of emphysema (Online Table 2 ). Cox's regression analysis unadjusted HR indicated that patients with 6 MWD ( 334 m), 6MWSpeed ( 0.9 m/sec), 6 MWW ( 20000 m kg), DSP ( 290 m%), BODE index (!4 points), EID (SpO 2 post 88%) or unintended stop(s) have a relative higher risk for mortality ( Fig. 1) . Additionally, the unadjusted HR for the prediction of hospitalization revealed that patients with 6 MWD ( 357 m), 6MWSpeed ( 1.0 m/sec), 6 MWW ( 27000 m kg), DSP ( 310 m%), BODE index (!3 points), EID (SpO 2 post 88%), or unintended stop(s) were more likely to be hospitalized during the 3-year follow-up (Fig. 2 ). An adjusted Cox's proportional-hazard regression model for age, sex, BMI, FEV 1 , FEV 1 /FVC ratio, SGRQ, emphysema, and smoking, indicated that the risk for mortality remained high for subjects with impaired 6 MWT-derived variables, EID and unintended stop(s) during the 6 MWT. Interestingly BODE index did not remain significant after the adjustment (Table 5 ). Regarding to hospitalization, 6 MWW, EID and the BODE index remained significant in the adjusted regression model.
Posterior Cox's regression analyses, which were performed on patients with impaired 6 MWT-derived variables according to the proposed cut-off points, incidence of EID and increased BODE index to predict mortality and hospitalization respectively (Tables 3 and 4 ), demonstrated that unintended stop(s) during the 6 MWT retained an additional negative impact on survival (Fig. 3 ). However, this was not observed for hospitalization-free probability (Online Fig. 1 ).
Discussion
This study explores the prognostic value of the 6 MWT-derived variables including 6 MWD, 6MWSpeed, 6 MWW, DSP, EID, and unintended stop(s) for the prediction of mortality and hospitalization during a 3-year follow-up in patients with COPD. The 6 MWD data of the ECLIPSE has been already investigated [2, 22, 23] , however, the essential novelty of our approach is that we demonstrated the 6 MWT-derived variables in association with mortality and hospitalization.
We found that unintended stop(s) during the 6 MWT can be a prognostic factor for mortality and hospitalization ( Figs. 1 and 2) . Interestingly, unintended stop(s) together with the rest of 6 MWTderived variables can refine the prognosis to predict mortality (Fig. 3) . Unintended stop(s), which can also lead to withdrawal from the 6 MWT, may reflect the overall impact of poor 6 MWT-derived variables and increased BODE index on patients' functional capacity. However, unintended stop(s) combined with impaired 6 MWTderived variables did not lend support in the prediction of hospitalization (Online Fig. 1) . A possible explanation could be that patients with poor 6 MWT-derived variables of 6 MWD, 6MWSpeed, 6 MWW, DSP, incidence of EID and increased BODE index, usually experience the first severe exacerbation related to hospitalization before there is an impact on their ability to keep a continuous pace during the 6 MWT. Using an adjusted Cox's proportional-hazard regression model, the prognostic value of unintended stops to predict mortality remained after adjustment for age, sex, BMI, FEV 1 , FEV 1 /FVC, SGRQ, emphysema, and smoking suggesting that unintended stop(s) can be an important prognostic outcome for survival (Table 5 ). To the best of our knowledge, this is the first study that demonstrates the prognostic value of unintended stop(s) during the 6 MWT in patients with COPD and suggests that more attention should be given to this outcome for the identification of high-risk patients.
Comparison with other studies
The 6MWSpeed has been already shown as a functional capacity indicator in 511 patients with mild to severe COPD [10] . A mean 6MWSpeed <1.0 m/s has been related to disability, hospitalization and decreased survival in older adults [5, 10] . A mean 6MWSpeed 0.9 m/sec increased the risk of death while 6MWSpeed 1.0 m/ sec increased the risk of hospitalization in our patients with COPD, respectively. The present study is the first one which provides certain cut-off points for the 6MWSpeed with prognostic value on mortality ( Fig. 1B) and on hospitalization (Fig. 2B ) in COPD patients.
In the study of Chuang and colleagues [25] , 6 MWW was used to assess work and energy expenditure during the 6 MWT demonstrating a better correlation with the anaerobic threshold, peak oxygen uptake, DLCO and vital capacity when compared to 6 MWD. Carter and colleagues [12] reported that 6 MWW is an improved outcome measure with a solid physiologic foundation for the assessment of functional capacity in COPD. DSP variable has also been shown to be a potential indicator of functional status in patients with sarcoidosis [26] while DSP <200 m% has been associated with a seven-fold greater risk of 12-month mortality in patients with idiopathic pulmonary fibrosis (IPF) [14] . The prognostic value of 6 MWW and DSP to predict mortality and hospitalization has also been confirmed by our findings (Figs. 1e2C & D) .
Other studies have demonstated that the levels of oxygen saturation and incidence of EID during the 6 MWT could improve the predictive ability of the 6 MWD in COPD patients [27, 28] . In this study, the occurence of EID was also an indicator for increased mortality and hospitalization. Beside the prognostic value of worse 6 MWT-derived variables, we also observed that older patients with lower FEV 1 and increased scores of SGRQ have higher risk for mortality and hospitalization (Online Fig. 2 ). Regarding to the BODE index, a study of Ong and colleagues [18] in 127 COPD patients who were followed up for 16 months demonstrated the BODE index as a better predictor of hospitalization for COPD than the FEV 1 alone. Previously, BODE score of 3 points or higher has been associated to mortality and exacerbation rates in patients with COPD [29] . Our findings suggested that increased BODE score was an independent predictor of mortality and hospitalization in our large cohort of COPD patients (Figs. 1e2E & F) .
A Cox's regression analysis with proportional hazard model for the prediction of 3-year mortality and hospitalization adjusted for Table 5 Adjusted hazard ratio of the 6MWT-derived variables and the BODE index for mortality and hospitalization during a 3-year follow-up. (Table 5 ). After this adjustment, the cutoff point used for DSP ( 290 m%) was the best predictor of mortality (Hazard Ratio: 2.70) while, suprisingly, the BODE index did not remain significant. We assume that the inclusion of SGRQ and BMI in the adjustment of regression model reduced the BODE index significance as a result of variables' interrelation. In terms of hospitalization, patients with worse 6 MWW, BODE index and EID had higher risk of exacerbation-related hospitalization ( Table 5 ). The cut-off point of the BODE index (!3 points) appeared to be the strongest predictor (Hazard Ratio: 1.40). Our adjusted proportional hazard models demonstrated that DSP is the stronger predictor of mortality while the BODE index is the most sensitive tool for the prediction of hospitalization compared to the 6 MWT-derived variables.
Strengths and weaknesses
There are certain limitations to our study. First, the 6 MWT screening was performed only once at baseline, while the 2014 ERS/ ATS Technical Standard for field walking tests suggest the conduct of two 6 MWT [30] . At the time of designating the ECLIPSE study, the 2002 ATS statement on 6 MWT was used, which did not recommend a practice walk. The 6 MWT-derived variables, such oxygen saturation, are reproducible [31] . Obviously, 6 MWW and DSP may have been a little bit higher as a second 6 MWT will increase the 6 MWD in about 80% of the patients with COPD [31] . Second, the number of the unintended stops during the 6 MWT is not available; nevertheless, the total walking time indicated whether or not patients stopped to rest during the 6 MWT. Third, the EID was defined based on the SpO 2 at the end of the test (SpO 2 post) and not the SpO 2 nadir which can lead to an overestimation of the DSP in patients who exhibit EID during the 6 MWT. Even though SpO 2 nadir and the SpO 2 post for most patients with chronic respiratory disease are relatively similar during the 6 MWT with differences ranging from 1% to 10% [32] , the use of SpO 2 nadir would be optimal absent the biases. Concerning the diagnostic accuracy, the area under a ROC curve quantifies the overall ability of the tested variables to discriminate between patients who have a good or poor prognosis. Even though the diagnostic accuracy of the 6 MWT-derived variables can be considered as sufficient based on the AUC (!0.60) [33] , a range of values is rather low (<0.60). In turn, omissions errors and commission errors may occur [34] . 
